According to clinical trials, prescription GLP-1 medications typically lead to 518% weight loss, while studies of high-dose tirzepatide combined with intensive lifestyle support have reported reductions of up to ~25%
Experimental use of this peptide assists in clarifying the structure-activity relationships essential for the development of next-generation neuroactive peptides, providing insights into the design of molecules with improved specificity and efficacy
Although preliminary findings indicate that GLP-1Ra causes modest bone mineral density reduction and enhances bone remodeling, favoring resorption similar to the effects of calorie restriction, further research is needed on fracture-related outcomes in people living with obesity
They are not temporary interventions
Author contributions NA: Conceptualization, Supervision, Writing review and editing
Influence of different prebiotics and mode of their administration on broiler chicken performance